Company Applies to Legally Mass-Produce Controlled Drugs
Published Date: 11/26/2025
Notice
Summary
Irvine Labs Inc. wants to make large amounts of some powerful, tightly controlled drugs like psilocybin and LSD for research. People and companies involved with these drugs can share their thoughts or ask for a hearing by January 26, 2026. This move could boost scientific studies but also means careful government oversight and no quick cash changes for now.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Application to Manufacture Schedule I Drugs
On October 29, 2025, Irvine Labs Inc. applied to be registered as a bulk manufacturer for several Schedule I substances, including ibogaine, lysergic acid diethylamide (LSD), mescaline, peyote, diethyltryptamine (DET), dimethyltryptamine (DMT), psilocybin, and psilocyn. The company says it plans to manufacture these drugs in bulk for research and development and to distribute them to its research customers.
Comment and Hearing Deadline
Registered bulk manufacturers of the affected drug classes, and applicants, may submit electronic comments or objections and may file written requests for a hearing on this application on or before January 26, 2026. Comments must be submitted through https://www.regulations.gov.
Registration Limited to Research Use
The notice states that, if registered, Irvine Labs' authorization would be limited to bulk manufacture of the listed drug codes for research and development internally and for distribution to its research customers. The registration would not authorize any other activities for those drug codes.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-21186, Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solutions, LLC
Organix Chemistry Solutions, LLC wants to become a big-time maker of some powerful controlled substances like LSD and marijuana. If you have thoughts or concerns, you’ve got until January 26, 2026, to speak up or ask for a hearing. This move could shake up who’s allowed to produce these drugs, so keep an eye on the deadline and get involved if you want!
Next: 2025-21188, Proposal Review; Notice of Meetings
The National Science Foundation (NSF) will hold closed meetings all year to review and decide on funding proposals for research projects. These meetings protect private info and won’t be open to the public, but you can check the NSF website for schedules and updates. This keeps the funding process fair and secure, with no direct cost changes announced.